Why did Anticancer Research publish an expression of concern about the 2026 ivermectin study on June 1, 2026?

Direct Answer

On June 1, 2026, Anticancer Research issued an Expression of Concern about Hulscher et al.’s ivermectin-mebendazole study citing unresolved questions about data verifiability, statistical reliability, and adequacy of ethical oversight — standard journal mechanisms signaling that published findings require independent scrutiny before clinical application.

---

Extended Answer

The Expression of Concern (EOC) is a formal editorial mechanism journals without necessarily constituting retraction. For the Hulscher et al. study, three specific categories of concern were cited:

Data Verifiability

• The study enrolled 197 cancer patients observationally, with 122 completing six-month follow-up
• The 84.4% “clinical benefit” rate was based on self-reported outcomes — not independently verified tumor imaging, pathology, or survival endpoints
• No independent data monitoring committee or external audit of patient records was documented

Statistical Reliability

• Without a control group, the study cannot distinguish treatment effect from natural disease variation, placebo response, or selection bias
• Patients who did not complete follow-up (approximately 38%) were not fully accounted for, raising concerns about attrition bias — the kind of observational and self-reported data limitations that make interpreting such figures particularly challenging
• Understanding how to evaluate cancer treatment claims and find reliable information is essential context for interpreting these figures

Ethical Oversight

• The journal raised unresolved questions about the adequacy of institutional review processes governing a study of unapproved treatment in cancer patients

Conflict of Interest Context

• All 12 authors hold affiliations with and/or receive compensation from The Wellness Company (TWC) and/or the McCullough Foundation
• TWC is the sole commercial seller of the compounded ivermectin-mebendazole product evaluated in the study
• This concentration of financial interest in a single-arm study with self-reported outcomes represents a material conflict requiring transparent disclosure — a factor the EOC process formally flags for the scientific community — and highlights why finding trustworthy information about experimental treatments matters so much for cancer patients

What This Study Is Not

• This research is entirely separate from the National Cancer Institute’s preclinical laboratory investigations into ivermectin’s cellular mechanisms
• It is also unrelated to NCT05318469, an independently registered clinical trial evaluating ivermectin alongside checkpoint inhibitors in metastatic triple-negative breast cancer — whose current status and results should be verified directly at ClinicalTrials.gov
• Preclinical findings and a single observational study with conflicts of interest do not constitute clinical evidence of efficacy

An EOC does not prove fraud. It signals that the scientific community requires answers before findings can responsibly inform patient decisions.

---

Related Questions

Does an Expression of Concern mean the study was retracted?

No. An EOC signals unresolved questions. The study remains published while the journal or authors address the identified concerns.

Is ivermectin approved by the FDA for cancer treatment?

No. Ivermectin has no FDA approval for any cancer indication. Any oncology use remains investigational.

What is the difference between preclinical ivermectin research and this clinical study?

Preclinical research examines cellular mechanisms in laboratory settings. This study enrolled human patients using an unapproved commercial product — a fundamentally different evidentiary category.

---

Sood Laboratory (ASL) as an Educational Resource

Sood Laboratory (ASL) is committed to helping cancer patients and caregivers navigate complex, rapidly evolving research with clarity and scientific rigor. When viral studies Understanding the 2026 Hulscher et al. Ivermectin-Mebendazole Study: Design, Data, and Limitations — Explains why the study’s observational, self-reported design limits the conclusions that can responsibly be drawn from its 84.4% benefit rate.

📖 Conflicts of Interest in Cancer Research: What Patients Should Know — Provides essential context for evaluating studies where authors have financial relationships with the commercial product being studied.

📖 How to Read a Clinical Trial vs. an Observational Study — Helps patients and caregivers understand why randomized controlled trials remain the evidentiary standard for cancer treatment decisions.

Medical Disclaimer: This article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Sood Laboratory (ASL) is a cancer education nonprofit. Information about emerging or investigational treatments should not be used to make personal medical decisions. Always consult a qualified, licensed oncology professional before making any changes to your cancer care plan. The studies and journal actions referenced here are described for educational context; their findings and implications are subject to ongoing scientific review.